Clinical impact of suboptimal RAASi therapy following an episode of hyperkalemia

Clinical impact of suboptimal RAASi therapy following an episode of hyperkalemia

Abstract Background Hyperkalemia (HK) is a barrier to optimization of renin-angiotensin-aldosterone system inhibitor (RAASi) therapy in heart failure (HF) and chronic kidney disease (CKD). We investigated cardiorenal risk associated with changes in RAASi regimen after an episode of HK in patients wi...

Full description

Bibliographic Details
Main Authors: Eiichiro Kanda, Anjay Rastogi, Toyoaki Murohara, Eva Lesén, Abiy Agiro, Matthew Arnold, Gengshi Chen, Toshitaka Yajima, Krister Järbrink, Charles V. Pollack
Format: Article
Language:English
Published: BMC 2023-01-01
Series:BMC Nephrology
Subjects:
Hyperkalemia
Heart failure
Chronic kidney disease
Guideline-directed medical therapy
Potassium binder
Online Access:https://doi.org/10.1186/s12882-022-03054-5

Internet

https://doi.org/10.1186/s12882-022-03054-5

Similar Items